Voyager Therapeutics is trading at $3.21 (+5.25%) in pre-market sessions as the stock gains momentum despite a lack of fresh company-specific announcements.
- The move likely reflects spillover optimism from a broader risk-on trading environment and positive sentiment across the biotechnology sector, with major U.S. indices and futures trending higher.
- Recent fundamental drivers remain supportive, including updated preclinical data for VY1706 and a reiterated Buy rating from H.C. Wainwright, though these items were published prior to today's move.